Skip to main content

Table 1 Baseline characteristics of patient cohort and the different persistent disease activity groups

From: Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group

Variable name Cohort (n = 385) Remission
Low pRLDA (n = 90) Moderate pMDA (n = 295) Lower-moderate plMDA (n = 133) Higher-moderate phMDA (n = 162)
Femalesa,b 293 (76%) 52 (58%) 241 (82%) 102 (78%) 139 (86%)
Age (years)a,b 56.35 ± 13 51.96 ± 13 57.69 ± 12 55.11 ± 12.31 59.81 ± 11.59
RA duration (years) 9.2 ± 8.6 9.57 ± 10 9.1 ± 8.12 8.71 ± 7.71 9.43 ± 8.45
RA duration < 2 years 70 (18%) 22 (24%) 48 (16%) 20 (15%) 28 (17%)
Seropositive* (n = 217) 100 (46%) 15 (47%) 85 (46%) 37 (51%) 48 (43%)
TJC28* (n = 316)a,b 10.53 ± 6.5 7.93 ± 6.3 11.14 ± 6.4 9.61 ± 5.56 12.39 ± 6.74
SJC28* (n = 316)a,b 8.99 ± 6.24 6.17 ± 6.1 9.66 ± 6.1 8.14 ± 5.55 10.89 ± 6.26
ESR* mm/s (n = 256) 38.62 ± 24 35.37 ± 23 39.4 ± 24 37.86 ± 23.42 40.63 ± 25.02
CRP* mg/dl (n = 227)a 2.57 ± 6 4.07 ± 12 2.22 ± 3.15 2.31 ± 3.32 2.15 ± 3.02
DAS28 (imputed)b 5.7 ± 0.99 4.92 ± 1 5.94 ± 0.86 5.62 ± 0.74 6.02 ± 0.86
CDAI* (n = 296)b 33 ± 12.19 26.06 ± 12 34.6 ± 12 30.86 ± 10.05 37.62 ± 12.13
SDAI* (n = 261)b 35.34 ± 13 29.99 ± 17 36.64 ± 12 32.66 ± 10.44 39.63 ± 12.18
Physician VAS G.* (n = 298)a,b 69.5 ± 14.8 62.92 ± 16 71.13 ± 14 67.57 ± 15.12 73.97 ± 12.7
Patient VAS G.* (n = 315)b 66.11 ± 19 59.43 ± 25 67.69 ± 17 63.74 ± 17.82 70.93 ± 15.54
Patient VAS Pain* (n = 302) 67.41 ± 17 62.93 ± 25 68.5 ± 17.2 66.26 ± 18.57 70.38 ± 15.87
HAQ (imputed)a,b 0.84 ± 0.44 0.63 ± 0.4 0.9 ± 0.5 0.77 ± 0.43 1 ± 0.45
Euroqol* (n = 82) 0.34 ± 0.38 0.36 ± 0.4 0.34 ± 0.39 0.4 ± 0.34 0.26 ± 0.43
Previous csDMARDs 2.34 ± 1.13 2.11 ± 0.9 2.41 ± 1.18 2.34 ± 1.25 2.46 ± 1.11
Ongoing csDMARDs 1.15 ± 0.57 1.15 ± 0.6 1.15 ± 0.6 1.1 ± 0.63 1.19 ± 0.53
Monotherapy b 32 (8%) 7 (8%) 25 (9%) 16 (12%) 9 (6%)
Methotrexate 279 (73%) 62 (69%) 217 (74%) 97 (73%) 120 (74%)
Anti-TNF b 350 (90%) 88 (98%) 262 (89%) 124 (93%) 138 (85%)
Prednisolone 184 (48%) 44 (49%) 140 (48%) 71 (53%) 69 (43%)
  1. Results presented as counts n (%) or mean (± sd)
  2. *Missing data > 5%
  3. aGroup pRLDA is significantly different from pMDA (Wilcoxon rank-sum test p < 0.05)
  4. bGroup plMDA is significantly different from phMDA (Wilcoxon rank-sum test p < 0.05)
  5. TJC28 Tender Joint Count 28, SJC28 Swollen Joint Count 28, ESR erythrocyte sedimentation rate, CRP C reactive protein, DAS28 Disease Activity Score 28 ESR4, CDAI Clinical Disease Activity Index, SDAI Simplified Disease Activity Index, VAS visual analog scale 100, Physician VAS G. physician VAS global, Patient VAS G. patient VAS global, HAQ Health Assessment Questionnaire, csDMARDs conventional synthetic disease-modifying antirheumatic drugs, Anti-TNF TNFα inhibitors
\